Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CRBP, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| capcitabine | Oropharyngeal Carcinoma (OPC) | Phase 3 · NCT07768189 | Recruiting |
| Sutantatug Envedotin (CRB-701) | Oropharyngeal Carcinoma (OPC) | Phase 3 · NCT07768189 | Recruiting |
| Lenabasum | Dermatomyositis | Phase 3 · NCT03813160 | Completed |
| Anti-PD-1 | Solid Tumor, Adult | Phase 1/2 · NCT06265727 | Recruiting |
| Anti-PD1 Monoclonal Antibody | Solid Tumor | Phase 1/2 · NCT06603844 | Recruiting |
| Anti-integrin AlphaV/Beta8 Monoclonal Antibody… | Solid Tumor | Phase 1/2 · NCT06603844 | Recruiting |
| JBT-101 | Cystic Fibrosis | Phase 2 · NCT02465450 | Completed |
| Part B Open-Label Extension | Diffuse Cutaneous Systemic Sclerosis | Phase 2 · NCT02465437 | Terminated |
| CRB-913 | Obese But Otherwise Healthy Participants | Phase 1 · NCT07310901 | Completed |
Also used in these trials (approved or third-party drugs, not CRBP's own candidates): Cetuximab, Docetaxel Anhydrous.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CRBP holds $115.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.4M/quarter from operations, an estimated runway of 13.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRBP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 1,914,788 | 9.29% | 2026-09-23 |
| MPM BioImpact LLC | Institution (13G, 5%+) | 1,667,272 | 8.09% | 2026-09-30 |
| Cormorant Asset Management, LP Former 10% Owner |
Insider | 1,500,000 | 7.28% | 2026-10-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 1,093,434 | 5.31% | 2026-06-30 |
| Yuval Cohen Chief Executive Officer, Director · +172,106 options |
Insider | 157,316 | 0.76% | 2026-08-07 |
| Dominic Smethurst Chief Medical Officer · +85,095 options |
Insider | 89,790 | 0.44% | 2026-03-02 |
| Sean F. Moran Chief Financial Officer · +94,633 options |
Insider | 84,694 | 0.41% | 2026-08-07 |
| Nishant C Saxena Chief Business Officer · +192,300 options |
Insider | 77,900 | 0.38% | 2026-08-11 |
| Leonardo Viana Nicacio Chief Medical Officer · +191,676 options |
Insider | 58,333 | 0.28% | 2026-08-16 |
| Ian Hodgson Chief Operating Officer · +85,095 options |
Insider | 51,080 | 0.25% | 2026-02-17 |
| Winston Kung Director · +16,000 options |
Insider | 12,140 | 0.06% | 2026-06-10 |
| Rachelle Suzanne Jacques Director · +16,000 options |
Insider | 11,383 | 0.06% | 2026-05-19 |
Share count 20,606,760 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRBP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →